Proteomics applications in biomedical research can largely be categorized into discovery and targeted-validation phases. Discovery-phase proteomics refers to the large-scale identification and quantification of proteins or protein posttranslational modifications from a complex biological sample such as cells in culture, tissues, or plasma. High-resolution and rapid-sampling mass spectrometers that are operating in a data dependent mode (i.e., collecting data in real time) are the foundation of discovery-phase proteomics. Discovery-phase proteomics generally utilizes 10s of samples and generates 1000s of candidate proteins for follow-up studies. Targeted-validation proteomics typically follows the discovery phase. For targeted-validation proteomics, specialized mass spectrometers are used to specifically quantify the levels of a small set of proteins in a large number of samples. Targeted-validation proteomics generally utilizes 1000s of samples to measure 10s of target proteins. The specific types of mass spectrometers, methods, data analysis strategies, and technical expertise are all different for discovery and targeted-validation proteomics; accordingly, many proteomics core facilities are specialized in one or the other proteomics subspecialty. The IDeA National Resource for Proteomics offers investigators access to instrumentation and services for both phases of proteomics research through one resource.
For more information on discovery-phase proteomics and the UAMS Proteomics Core Facility, see the UAMS Facilities page.
For more information on targeted-validation proteomics and the OMRF Multiplexing Protein Quantification Core, see the OMRF Facilities page.